Back to Search
Start Over
Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes
- Source :
- European Journal of Clinical Pharmacology. 65:601-608
- Publication Year :
- 2009
- Publisher :
- Springer Science and Business Media LLC, 2009.
-
Abstract
- To investigate the interaction between allicin and omeprazole and to observe the effects of allicin on CYP2C19 and CYP3A4 activity in healthy Chinese male volunteers with different CYP2C19 genotypes. Eighteen subjects (six CYP2C19*1/CYP2C19*1, four CYP2C19*1/CYP2C19*2, two CYP2C19*1/ CYP2C19*3, and six CYP2C19*2/ CYP2C19*2) were enrolled in a two-phase randomized crossover trial. In each phase, all subjects received placebo or a 180 mg allicin capsule once daily for 14 consecutive days. The pharmacokinetics of omeprazole (20 mg orally on day 15) was determined for up to 12 h following administration by high-performance liquid chromatography. In carriers of the CYP2C19*1/CYP2C19*1 and CYP2C19*1/CYP2C19*2 or *3 genotype, allicin treatment increased the peak plasma concentration (Cmax) of omeprazole by 49.7 ± 7.2 (p
- Subjects :
- Male
medicine.medical_specialty
Genotype
medicine.drug_class
Cmax
Proton-pump inhibitor
CYP2C19
Pharmacology
Placebo
Gastroenterology
Placebos
chemistry.chemical_compound
Pharmacokinetics
Reference Values
Internal medicine
medicine
Cytochrome P-450 CYP3A
Humans
Pharmacology (medical)
Disulfides
Chromatography, High Pressure Liquid
Omeprazole
Cross-Over Studies
Allicin
General Medicine
Anti-Ulcer Agents
Sulfinic Acids
Crossover study
Cytochrome P-450 CYP2C19
chemistry
Spectrophotometry, Ultraviolet
Aryl Hydrocarbon Hydroxylases
medicine.drug
Subjects
Details
- ISSN :
- 14321041 and 00316970
- Volume :
- 65
- Database :
- OpenAIRE
- Journal :
- European Journal of Clinical Pharmacology
- Accession number :
- edsair.doi.dedup.....874455fda46f66def2d4a24894e56684